Intellia Therapeutics Raises $175 Million in Public Offering
December 2, 2020
Rare Daily Staff
Just six months after raising $100 million in a public offering, Intellia Therapeutics is back in the public markets to raise another $175 million.
The genome editing biotech is offering 4.8 million shares of its common stock at $36.50 per share and has granted the underwriters a 30-day option to purchase up to an additional 719,178 shares.
Intellia Therapeutics uses CRISPR/Cas9 genome editing technology both in vivo and ex vivo to develop potentially curative therapeutics addressing a broad range of genetic and oncological diseases. It has collaborations with Regeneron for both in vivo and ex vivo product candidates that include hemophilia A and B, a partnership with Novartis in sickle cell disease and oncology, and several proprietary preclinical candidates in the pipeline.
The company also recently secured authorization from the United Kingdom Medicines and Healthcare products Regulatory Agency to begin a phase 1 study to evaluate its lead in vivo experimental therapy NTLA-2001 for the treatment of the rare, progressive, and fatal condition hereditary transthyretin amyloidosis with polyneuropathy.
Sign up for updates straight to your inbox.